Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Scinai Immunotherapeutics Ltd ADR
(NQ:
SCNI
)
3.710
+0.080 (+2.20%)
Streaming Delayed Price
Updated: 3:50 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Scinai Immunotherapeutics Ltd ADR
< Previous
1
2
3
Next >
Researchers Shine Spotlight on New Barriers to Vaccination
October 14, 2024
Via
Investor Brand Network
Exposures
COVID-19
Whooping Cough Prevalence Rises in US as Missed Shots During Pandemic Come Home to Roost
September 25, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Schedules Virtual Panel Discussion on Plaque Psoriasis, Its Promising Novel Solution
September 16, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Featured Guest on Latest Episode of BioMedWire Podcast
September 09, 2024
Via
Investor Brand Network
New Approach Could Boost Effectiveness of Immunotherapies Against Colorectal Cancer
September 04, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), EIB Close on Loan Restructuring Agreement
August 21, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Into $2M Investment Commitment Agreement with Its Largest Existing Shareholder
August 20, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q2 2024 Financial Results, Shares Business Update
August 15, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Signs Definitive Loan Restructuring Agreement with EIB Converting Debt into Equity
August 13, 2024
Via
Investor Brand Network
Australia Launches Novel Immunotherapy Program to Help Babies with Peanut Allergies
August 09, 2024
Via
Investor Brand Network
Study Highlights Heightened Risk of Diseases Spreading from Animals to Humans
July 26, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives PEI Feedback Regarding Development, Preclinical Trial of Anti-IL-17 NanoAb
July 23, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Successful Preclinical Results In-Vivo Proof-of-Concept Psoriatic Human Skin Model Study
July 15, 2024
Via
Investor Brand Network
Study Explores Starving Malignant Cells to Boost Immunotherapy, Improve DNA Damage
July 12, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Updated LoI from the European Investment Bank
July 08, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Q1 2024 Financial Reports, Business Update
July 02, 2024
Via
Investor Brand Network
Study Finds Infectious Diseases Have Surged Post COVID-19 Pandemic
June 26, 2024
Via
Investor Brand Network
Exposures
COVID-19
BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives LOI with European Investment Bank for Loan-to-Equity Conversion
June 13, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Regains Compliance with Nasdaq Listing Rule 5550(a)(2)
June 07, 2024
Via
Investor Brand Network
NIH Researchers Unveil AI Tool to Predict Oncology Patients’ Response to Immunotherapy
June 07, 2024
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Study Offers Insights on Why Autoimmune Conditions Disproportionately Afflict Women
May 20, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases FY 2023 Financial Results, Provides Business Update
May 16, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Nasdaq Delisting Notification and Appeal, ADS Ratio Change
May 06, 2024
Via
Investor Brand Network
Vitamin D Could Balance Gut Microbiota, Boost Cancer Immunotherapy
May 01, 2024
Via
Investor Brand Network
Study Finds Presurgery Immunotherapy Safe for Patients with Pancreatic Cancer
April 12, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Chief Science Officer to Present at This Month’s Europe Dermatology Drug Development Summit
April 10, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), Scinai Bioservices Enter MSA with Ayana Pharma
April 08, 2024
Via
Investor Brand Network
Gene Signature Could Predict NSC Lung Cancer Response to Immunotherapy
March 22, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Showcasing Services, Meeting with Investors at Upcoming BIO-Europe Spring 2024
March 12, 2024
Via
Investor Brand Network
Siteman Cancer Center Starts Offering Novel Cell-Based Immunotherapy Against Melanoma
February 28, 2024
Via
Investor Brand Network
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.